Liquidia Technologies, Inc. (NASDAQ:LQDA) General Counsel Sells $111,898.08 in Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 7,836 shares of Liquidia Technologies stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $14.28, for a total value of $111,898.08. Following the completion of the transaction, the general counsel directly owned 577,977 shares in the company, valued at approximately $8,253,511.56. This represents a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Technologies Stock Up 2.9%

Shares of NASDAQ LQDA traded up $0.41 during midday trading on Thursday, hitting $14.60. 1,563,026 shares of the stock traded hands, compared to its average volume of 1,308,757. The business has a 50 day moving average price of $14.89 and a two-hundred day moving average price of $14.46. Liquidia Technologies, Inc. has a one year low of $8.26 and a one year high of $19.41. The company has a market cap of $1.25 billion, a PE ratio of -9.24 and a beta of -0.01. The company has a debt-to-equity ratio of 2.08, a quick ratio of 2.91 and a current ratio of 2.93.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. The company had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. On average, equities analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Liquidia Technologies

Several institutional investors have recently bought and sold shares of the stock. Corebridge Financial Inc. grew its holdings in Liquidia Technologies by 2.3% during the fourth quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock worth $371,000 after buying an additional 694 shares in the last quarter. Ballentine Partners LLC boosted its position in Liquidia Technologies by 10.2% in the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company's stock worth $151,000 after purchasing an additional 1,119 shares during the last quarter. GAMMA Investing LLC boosted its position in Liquidia Technologies by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after purchasing an additional 1,173 shares during the last quarter. Cetera Investment Advisers boosted its position in Liquidia Technologies by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after purchasing an additional 1,277 shares during the last quarter. Finally, Valmark Advisers Inc. boosted its position in Liquidia Technologies by 7.4% in the first quarter. Valmark Advisers Inc. now owns 18,641 shares of the company's stock worth $275,000 after purchasing an additional 1,283 shares during the last quarter. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Raymond James Financial lifted their target price on Liquidia Technologies from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Wall Street Zen upgraded Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Needham & Company LLC reiterated a "buy" rating on shares of Liquidia Technologies in a report on Monday, June 2nd. HC Wainwright lifted their target price on Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, May 28th. Finally, Scotiabank lifted their target price on Liquidia Technologies from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $26.89.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).